Rocket Pharmaceuticals Insider Sarbani Chaudhuri Sells $11.3K of Stock
Sarbani Chaudhuri sold 4,872 shares of Rocket Pharmaceuticals, Inc. at $2.33 a share, worth $11.3K in total on Nov 9, 2026. Shares held after the trade: 257,937 (-1.9%).
Rocket Pharmaceuticals reported third quarter 2026 financial results, highlighting FDA alignment on the pivotal Phase 2 trial for RP-A501 in Danon disease with dosing completion expected by mid-2027. The company ended the quarter with $279.4 million in cash and investments, which is expected to fund operations into the third quarter of 2028.
Term
Q3 2026
“With FDA alignment on the pivotal RP-A501 trial in Danon disease, our priority is to complete dosing by mid-2027. We are also advancing our broader cardiovascular portfolio, with dosing initiated in the Phase 1 trial of RP-A701 for BAG3-DCM and continued FDA engagement on a potential pivotal study of RP-A601 in PKP2-ACM. Commercial readiness for KRESLADI and activation of our first Qualified Treatment Centers bring us closer to treating eligible children. Our financial resources and the additional flexibility provided by the Hercules facility support these priorities as we work toward our next clinical and commercial milestones.”
Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on genetic medicines for rare diseases. As of September 30, 2026, the company is classified as a non-accelerated filer and smaller reporting company with 111,660,283 shares of common stock outstanding.
Rocket Pharmaceuticals General Counsel Martin Wilson Sells $128K of Stock
Martin Wilson, General Counsel, sold 53,389 shares of Rocket Pharmaceuticals, Inc. at $2.39 a share, worth $128K in total on Nov 5, 2026. Shares held after the trade: 545,100 (-8.9%).
Rocket Pharmaceuticals $150M Debt Financing with Hercules Capital, Inc.
Rocket Pharmaceuticals entered into a senior secured term loan agreement with Hercules Capital for up to $150.0 million across five tranches. The company received an initial $35.0 million at closing, with subsequent tranches available upon clinical milestones and lender approval to support its Phase 2 study of RP-A501 for Danon disease.